ABCs in Dermatology: Late Breaking Data Spotlight at AAD 2026

For dermatologists and the dermatology community, the 

American Academy of Dermatology (AAD) Annual Meeting

 has earned the reputation as a platform the next wave of practice-changing advances in the field. The 2026 AAD annual meeting served as a prime example of why, with more than a dozen phase 2 or phase 3 trials headlining the conference—showcasing new data in psoriasis, atopic dermatitis, and more.

hosts Chris Bunick, MD, PhD, of Yale School of Medicine, and Lindsay Ackerman, MD, of US Dermatology Partners, break down a trio of late-breaking trials from the meeting and share their perspective on additional data of note across multiple disease states.

On March 28, 2026, Eli Lilly announced positive phase 3b results from the TOGETHER-PsA trial evaluating concomitant ixekizumab (Taltz) and tirzepatide (Zepbound) versus ixekizumab alone in adults with active psoriatic arthritis and obesity or overweight.

In the randomized, open-label trial of 271 participants, the combination arm met the primary endpoint, ACR50 response plus ≥10% weight reduction at 36 weeks, in 31.7% of patients versus 0.8% with ixekizumab monotherapy, with improvements in disease activity, fatigue, physical function, and cardiometabolic markers also favoring the combination. Adverse events in the combination arm were generally mild to moderate and consistent with the established profiles of each agent, with nausea, diarrhea, and constipation among the most common.

Eli Lilly indicated detailed findings will be discussed with regulators, though no submission timeline was disclosed.

On March 23, 2026, Apogee Therapeutics announced positive 52-week maintenance data from Part A of the phase 2 APEX trial evaluating zumilokibart, an extended half-life anti-IL-13 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis.

Based on the trial's maintenance phase, EASI-75 response was maintained at week 52 in 75% and 85% of week 16 responders receiving every-3-month and every-6-month dosing, respectively, with deepening of response observed across lesional and itch endpoints in the full treated population through 52 weeks. Zumilokibart's extended half-life design supports dosing as infrequently as twice yearly, compared with up to 26 annual injections for currently available therapies, with a safety profile consistent with other agents in the IL-13 class.

Part B 16-week induction data are expected in the second quarter of 2026, with phase 3 initiation in moderate-to-severe atopic dermatitis planned for the second half of 2026.

On March 28, 2026, Takeda announced positive phase 3 results from the Latitude PsO 3001 and 3002 trials evaluating zasocitinib, a once-daily oral selective TYK2 inhibitor, in adults with moderate-to-severe plaque psoriasis.

In the randomized, double-blind, placebo- and active comparator-controlled trials, 71.4% and 69.2% of zasocitinib-treated patients achieved sPGA 0/1 at week 16 versus 10.7% and 12.6% with placebo and 32.1% and 29.7% with apremilast (

<.001), with PASI 75 responses observed as early as week 4 and more than 90% of week 40 responders maintaining response through week 60. The safety profile was consistent with phase 2b data, with upper respiratory tract infection, nasopharyngitis, and acne among the most common adverse events and no new safety signals were identified.

Takeda plans to submit a New Drug Application to the FDA starting in fiscal year 2026.


Relevant disclosures for Bunick include AbbVie, South Beach Symposium, Almirall, Apogee Therapeutics, Arcutis Biotherapeutics, Daiichi Sankyo, Eli Lilly, LEO Pharma, US, Novan, Novartis, Ortho Dermatologics, Palvella Therapeutics, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Timber Pharmaceuticals, and UCB. Relevant disclosures for Ackerman include AbbVie, Alumis, Amgen, Arcutis, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, L'Oréal, Novartis, Sun Pharmaceutical, and UCB.

Eli Lilly and Company. Phase 3b data presented at AAD Annual Meeting show Lilly’s Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity | Eli Lilly and Company. Eli Lilly and Company. Published March 28, 2025. Accessed April 2, 2026. 

https://investor.lilly.com/news-releases/news-release-details/phase-3b-data-presented-aad-annual-meeting-show-lillys-taltz

Apogee Therapeutics. Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis | Apogee Therapeutics, Inc. Apogee Therapeutics, Inc. Published March 23, 2026. Accessed April 2, 2026. 

https://investors.apogeetherapeutics.com/news-releases/news-release-details/apogee-therapeutics-announces-positive-phase-2-part-52-week-datq

Takeda. Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care. Takeda.com. Published March 28, 2026. Accessed April 2, 2026. 

https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-phase3-clinical-trial-results/

Podcasts

Late-breaking AAD 2026 trials spotlight PsA weight-loss combo, twice-yearly IL-13 dosing for atopic dermatitis, and a rapid oral TYK2 pill for psoriasis.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

ABCs in Dermatology

Welcome to ABC’s in Dermatology, HCPLive’s newest dermatology podcast, hosted by a pair of the field’s leading minds in Lindsay Ackerman, MD, and Chris Bunick, MD, PhD.

Created by the same team behind The Medical Sisterhood and Skin of Color Savvy, ABCs in Dermatology is a monthly podcast designed to deliver candid conversations, clinical insight, and forward-looking perspectives from the voices shaping dermatology today.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Martina J. Porter, MD, is a dermatologist at Beth Israel Deaconess Medical Center.

Povorcitinib Delivers Deepening Responses Through 54 Weeks in Moderate-to-Severe HS, With Martina Porter, MD

An oral selective JAK1 inhibitor has demonstrated sustained and deepening clinical response through 54 weeks in moderate-to-severe 

, with up to 29% of patients achieving complete abscess and inflammatory nodule clearance — adding a mechanistically distinct option to a treatment landscape that has expanded rapidly but remained anchored to injectable biologics.

To discuss the findings, we spoke with Martina L. Porter, MD, of Harvard Medical School and Beth Israel Deaconess Medical Center in Boston, presenting author of the 54-week STOP-HS data at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

 held in Denver, Colorado, from March 27-31. STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836) are identically designed global phase 3 trials enrolling 1,227 adults total (STOP-HS1, n = 608; STOP-HS2, n = 619) with moderate-to-severe HS, randomized 1:1:1 to povorcitinib 75 mg once daily, 45 mg once daily, or placebo for a 12-week placebo-controlled period, followed by a 42-week blinded extension through week 54. Patients were required to have AN count ≥5 in ≥2 anatomic areas, Hurley stage II or III, disease duration ≥3 months, and prior systemic therapy — with 37.2% having previously received a biologic. Mean disease duration was 10.3 years (SD 9.4), mean AN count 12.0 (SD 8.8), and 75.5% had at least 1 draining tunnel at baseline.

At the primary endpoint of HiSCR50 at week 12, both doses were statistically significant versus placebo in both studies — 40.2% (45 mg) and 40.6% (75 mg) versus 29.7% placebo in STOP-HS1 (

 <.025), and 42.3% for both doses versus 28.6% placebo in STOP-HS2 (

 <.01) — with continuous improvement through week 54. By observed-cases analysis at week 54, HiSCR50 reached 60.2%–61.9% (STOP-HS1) and 57.3%–67.5% (STOP-HS2) in patients on continuous povorcitinib, with placebo crossover patients achieving comparable rates after switching at week 12. High-threshold responses deepened comparably, with up to 29.0% of patients achieving HiSCR100 at week 54. Full clearance of all inflammatory lesions (ANdT = 0) was achieved in 16.1%–20.2% of patients across both studies. Clinically meaningful improvements were observed across patient-reported outcome measures at week 54: ≥3-point decreases in skin pain NRS in 40.5%–58.0% of eligible patients, ≥4-point improvements in FATIGUE (FACIT-F) in 40.5%–49.0%, ≥4-point decreases in DLQI in 59.4%–64.7%, and ≥21-point decreases in HiSQoL total score in 33.7%–40.2%. 

Safety through week 54 was consistent with the class profile — the most common TEAEs were acne (16.4%–21.1%), nasopharyngitis (9.4%–13.6%), and upper respiratory tract infection (9.1%–12.2%). Serious TEAEs occurred in 3.7%–6.4% of patients across arms, with no malignancies excluding NMSC reported and MACE occurring in only 1 patient (0.3%) in STOP-HS2. Porter contextualized povorcitinib's JAK1 mechanism as genuinely complementary to existing options: while TNF-α and IL-17 inhibitors — including secukinumab, bimekizumab, and the phase 3-complete agents izokibep and imsidolimab — share overlapping proximity in the inflammatory signaling cascade, JAK-STAT pathway inhibition operates through a distinct mechanism that may benefit patients who have already failed biologic therapy, and Porter suggested it could potentially be considered first line pending the FDA approval pathway.

“For some patients who have already taken biologics and had very minimal response, this could be very promising for them especially. But I've also seen in clinical practice that it has a variety effects of on different types of HS patients, and so I also think it could be considered first line in the future as well, depending on how It's [potentially] approved through the FDA,” Porter said.

Relevant disclosures for Porter include Abbvie, Bristol Myers Squibb, Janssen, Eli Lilly, Novartis, Pfizer, UCB, Trifecta Clinical, Incyte, and Anaptys Bio.

Porter ML, Martorell A, Sayed CJ, et al. Povorcitinib in patients with moderate to severe hidradenitis suppurativa: 54-week efficacy and safety results from the STOP-HS1 & STOP-HS2 phase 3 studies. Presented at: American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO. Presentation 80034.

Videos

54-week data from the phase 3 STOP-HS1 and STOP-HS2 trials demonstrate JAK inhibitor povorcitinib's benefit in HS.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

Rethinking When and How to Treat IgA Nephropathy, With Sayna Norouzi, MD

The treatment landscape for IgA nephropathy is undergoing a profound transformation, driven by updated clinical guidelines, earlier diagnosis, and a rapidly expanding therapeutic arsenal. Where management was once largely reactive, the field is now moving toward earlier, more aggressive, and more targeted intervention aimed at altering disease trajectory.

 at World Congress of Nephrology in Yokohama, Japan, Sayna Norouzi, MD, a clinical nephrologist and associate professor of medicine at Loma Linda University Medical Center, said one of the most significant shifts between the 2021 and 2025 guidelines is the redefinition of high-risk disease.

Previously, proteinuria thresholds of around 1 gram per day were used to guide treatment escalation. Now, patients with proteinuria ≥0.5 g/day are considered at risk, representing a major change in how clinicians identify and manage disease severity. This lower threshold underscores a growing recognition that IgA nephropathy is not a benign condition and can lead to kidney failure if not addressed early.

“The sooner you diagnose these patients, [the sooner] you're going to be able to treat them, and with effective treatment of IgA nephropathy, you might be able to delay dialysis or transplant or complications in general, for your patients,” she said.

The updated guidelines also emphasize more ambitious treatment goals, with a target proteinuria level ideally < 0.3 g/day. Norouzi explains that this shift reflects mounting evidence linking lower proteinuria to improved long-term outcomes, including delayed progression to dialysis or transplant. As a result, clinicians are now encouraged to pursue tighter disease control from the outset.

Another key evolution lies in treatment strategy. Historically, care began with supportive measures like blood pressure control, lifestyle modification, and initiation of RAAS blockade, with additional therapies introduced only after inadequate response. In contrast, the 2025 guidance promotes a more proactive, simultaneous approach, and while supportive care remains foundational, clinicians are now urged to initiate therapies targeting the underlying pathophysiology earlier in the disease course rather than waiting for treatment failure.

This paradigm shift is enabled by a growing list of therapeutic options. Norouzi highlights the emergence of targeted agents, including targeted-release budesonide, endothelin receptor antagonists like sparsentan and atrasentan, complement inhibitors such as iptacopan, and newer APRIL-targeting therapies. Together, these agents provide clinicians with multiple avenues to reduce proteinuria and preserve kidney function.

Despite this progress, she says important questions remain. Norouzi notes that clinical trials provide only a limited snapshot of efficacy and safety, often over relatively short durations. As these therapies enter real-world practice, she says clinicians will need to better understand long-term tolerability, optimal sequencing, and effectiveness in more heterogeneous patient populations.

“We need more data on these medications, on the safety, on how they are going to work over time. The clinical trials are looking at a limited amount of time. They follow patients for 9 months for the initial outcome data, and then they follow patients for 2 years,” Norouzi said. “Once the medication is FDA approved and it's on the market, that's when we are going to have more information and see in real life if patients are tolerating the medications. We're going to hear more about the side effects, how to monitor these patients over time, and if they are responding well to the medications as well.”

Norouzi reports relevant disclosures with Calliditas, Travere, Apellis and others.

Brooks A. KDIGO Releases Updated IgA Nephropathy, IgA Vasculitis Clinical Practice Guideline. HCPLive. September 18, 2025. Accessed March 28, 2026. 

https://www.hcplive.com/view/kdigo-releases-updated-iga-nephropathy-iga-vasculitis-clinical-practice-guideline

Campbell P. Iptacopan Receives Accelerated Approval for Reducing Proteinuria in IgA Nephropathy. August 7, 2024. Accessed April 1, 2026. 

https://www.hcplive.com/view/iptacopan-receives-accelerated-approval-for-reducing-proteinuria-in-iga-nephropathy

Campbell P. Atrasentan (Vanrafia) Receives Accelerated Approval in IgA Nephropathy. April 2, 2025. Accessed April 1, 2026. 

https://www.hcplive.com/view/atrasentan-vanrafia-receives-accelerated-approval-in-igan

New IgAN guidelines emphasize earlier diagnosis, lower proteinuria targets, and combination therapy to delay kidney failure and improve long-term outcomes.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

Diabetes Dialogue: Orforglipron Receives FDA Approval for Chronic Weight Management

 has approved orforglipron (Foundayo), a once-daily oral GLP-1 RA, for chronic weight management in adults with 

 or overweight adults with ≥1 weight-related comorbidity.

In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA’s decision and the myriad new treatment opportunities afforded by orforglipron’s clearance for entry into the market.

The approval of orforglipron is supported by the phase 3 ATTAIN clinical development program, which includes 2 global, randomized, double-blind, placebo-controlled trials evaluating efficacy and safety over 72 weeks.¹ The ATTAIN-1 trial enrolled 3,127 adults with obesity or overweight without diabetes, while ATTAIN-2 enrolled more than 1,600 adults with obesity or overweight and type 2 diabetes.

In ATTAIN-1, participants receiving the highest dose of orforglipron achieved a mean weight reduction of approximately 12.4% from baseline at 72 weeks among those who remained on treatment, compared with 0.9% in the placebo group. Reported average absolute weight loss was 27.3 lb versus 2.2 lb, respectively. Across all randomized participants regardless of completion status, mean weight loss was 11.1% with orforglipron compared with 2.1% with placebo.

Secondary outcomes included improvements in cardiometabolic risk markers such as waist circumference, non–high-density lipoprotein cholesterol, triglycerides, and systolic blood pressure. However, detailed peer-reviewed data from ATTAIN-1 and ATTAIN-2 remain limited at the time of reporting, and full efficacy and safety results have not yet been widely published in the medical literature.

The safety profile of orforglipron appears consistent with the GLP-1 receptor agonist class. Common adverse events include gastrointestinal symptoms such as nausea, diarrhea, constipation, vomiting, and abdominal pain. A boxed warning highlights a potential risk of thyroid C-cell tumors, based on findings observed with other GLP-1 receptor agonists in rodent studies, though human relevance remains uncertain.

The magnitude of weight loss observed with orforglipron in ATTAIN-1 appears clinically meaningful but may be modest relative to leading injectable agents. Cross-trial comparisons should be interpreted cautiously due to differences in study populations and designs. Additionally, treatment persistence rates and discontinuation due to adverse events will be important considerations in real-world use.

Ongoing and planned studies are evaluating orforglipron across additional indications, including type 2 diabetes and other cardiometabolic conditions. Future comparative trials against established GLP-1 and dual incretin therapies may help define its role in treatment algorithms.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Eli Lilly. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. April 1, 2026. Accessed April 1, 2026. 

https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill

US Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. April 1, 2026. Accessed April 1, 2026. 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program

This episode addresses the groundbreaking approval of the first GLP-1 RA without timing or meal restrictions.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Mavacamten Safety and Real-World Data Emerging at ACC.26, With Matthew Martinez, MD

Real-world evidence continues to refine the clinical profile of mavacamten in 

obstructive hypertrophic cardiomyopathy (HCM)

, with new data from both the MARVEL-HCM cohort and a large US Risk Evaluation and Mitigation Strategy (REMS) registry analysis reinforcing its effectiveness and safety in routine practice.

, Matthew Martinez, MD, associate professor of medicine, director of sports cardiology, and director of the Hypertrophic Cardiomyopathy program at Morristown Medical Center/Atlantic Health System, discussed the emerging data from the MARVEL-HCM trial, presented at the 

American College of Cardiology (ACC) Scientific Sessions 2026

“Most often, patients will ask, ‘How long have you been using this drug?’ So, the value of long-term safety data continues to be helpful,” Martinez told 

. “When I’m educating patients about options, I don’t determine what therapy we’re going to use. I give them the option of what’s best for them, and then we can decide together which therapeutic option is the next best step. Ongoing, long-term data continues to be helpful in that discussion.”

In MARVEL-HCM, a multicenter study of 239 patients, women presented at an older age than men (68.5 vs 59.3 years) and with more advanced disease, including higher rates of New York Heart Association (NYHA) class III symptoms and more severe diastolic dysfunction. Over 48 weeks of treatment, patients experienced significant reductions in resting and Valsalva left ventricular outflow tract (LVOT) gradients, improved functional status, and decreased severity of mitral regurgitation. Left ventricular mass index declined in both groups, supporting a role for reverse remodeling, while left ventricular ejection fraction (LVEF) remained stable, and no new safety signals were observed.

These findings are complemented by data from a large REMS-based analysis including more than 6000 patients treated with mavacamten in the United States. In this real-world cohort, 60% of patients were women and nearly two-thirds were older than 60 years, reflecting a population similar to that seen in clinical practice. Over a follow-up period of up to 22 months, reductions in LVOT obstruction were observed, with 70.3% of patients achieving a post-Valsalva gradient <30 mm Hg at 6 months.

Among more than 5,500 patients in the REMS study with monitoring data, 4.6% experienced a reduction in LVEF to <50%, and only 1.3% required hospitalization for heart failure. At the level of individual assessments, these events were infrequent, occurring in <1% of evaluations. Most patients remained on low-dose therapy, with approximately three-quarters maintained on 5 or 10 mg daily.

Taken together, these datasets highlight several clinically relevant themes. First, mavacamten demonstrates consistent effectiveness across diverse patient populations, including those with more advanced disease at baseline. Second, the drug appears to exert favorable effects on cardiac structure and hemodynamics beyond symptom relief. Third, real-world safety outcomes - particularly the low incidence of systolic dysfunction and heart failure - support the feasibility of REMS-guided monitoring in routine care.

The MARVEL-HCM findings also underscore persistent sex-based disparities in disease recognition and severity at treatment initiation. Earlier diagnosis and referral, particularly among women, may further enhance the clinical benefits observed with mavacamten in obstructive HCM.

“I think the real-world data is going to be critical,” Martinez said. “You’re already seeing the ability to be a little more granular with some of the real-world data, such as MARVEL and COLLIGO, because it allows us to ask other questions that may not have been specifically addressed during the clinical trials that led to mavacamten’s approval. All of these real-world studies allow us just a glimpse into what’s happening outside of large academic centers.”

Editors’ Note: Martinez reports disclosures with Bristol Myers Squibb, Cytokinetics, Major League Soccer, and the NHL Combine.

1: Martinez M, Wheeler M, Mehra V, et al. Real-World Evidence from the MARVEL-HCM Multicenter Study of Mavacamten – A Sex-Based Analysis of Baseline Characteristics and Cardiac Structural and Functional Changes. Abstract presented at the American College of Cardiology Scientific Sessions 2026, New Orleans, LA. March 28-30, 2026.

2: Desai MY, Seto D, Cheung M, et al. Mavacamten: Real-world experience from 22 months of the risk evaluation and mitigation strategy (REMS) program. 

Martinez discusses the bigger picture of mavacamten, highlighting its safety and efficacy as well as recent real-world trial data in patients with HCM.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Cardiomyopathy

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

Eingun James Song, MD, discusses takeaways from his AAD session on addressing concerns of patients with psoriasis and skin of color.

Tips on Strategies for Psoriasis in Skin of Color, With Eingun James Song, MD

Joseph Rossano, MD, MS, is the co-director of the Cardiac Center and chief of the division of cardiology at the Children’s Hospital of Philadelphia, as well as the Jennifer Terker Endowed Chair in Pediatric Cardiology.

Rossano discusses the results of the phase 3 SCOUT-HCM trial, highlighting mavacamten’s comparative superiority in reducing left ventricular outflow.

SCOUT-HCM: Mavacamten Outperforms Placebo in Adolescents With HCM, With Joseph Rossano, MD, MS

Andres Gelrud, MD, is a gastroenterologist at Baptist Health Miami Cancer Institute, part of Baptist Health South Florida

Gerlud explains unmet needs in EPI, including underdiagnosed patient populations, and the intense pill burdens patients face. 

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Beyond Chronic Pancreatitis, Rethinking Who Gets EPI and How We Treat It, With Andres Gelrud, MD

Lingfeng Xue, PhD, an old age psychiatry and clinical research assistant at King’s College London.

Analysis of 75,064 UK Biobank participants found late-onset depression associated with worse fluid intelligence and visuospatial memory and a 42–52% increased dementia risk.


Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Dementia and Alzheimer Disease

Alzheimer Disease condition center page, resources on the topics of medical news and expert insight into Alzheimer's can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dementa and Alzheimer disease research, treatment, and drug development.

Late-Onset Depression Linked to Increased Dementia Risk, With Lingfeng Xue, PhD

Thierry Passeron, MD, PhD, is a professor and chair of the Department of Dermatology at the Université Côte d'Azur in Nice, France.

In this segment of his interview, Passeron speaks on the next steps for upadacitinib in non-segmental vitiligo (NSV).

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Next Steps for Upadacitinib in Non-Segmental Vitiligo, With Thierry Passeron, MD, PhD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Articles

The Agency approved Lilly’s orforglipron (Foundayo) for adults with obesity or overweight. It can be taken any time of the day without restrictions on food and water intake.

FDA News

FDA Approves Orforglipron (Foundayo) As First Daily GLP-1 Pill Without Food, Water Restrictions

Christopher Chan, MD, is director of the division of nephrology, professor of medicine, and R Fraser Elliott Chair in Nephrology at Toronto General Hospital, University Health Network.

Chan describes the current landscape of dialysis care and why home-based approaches are gaining momentum for patients with ESRD.

Chronic Kidney Disease

Entering A New Era of Flexible Dialysis Care, With Christopher Chan, MD

Sofia Holmqvist-Jämsén, PhD, from the University of Helsinki

A study shows that weekly or daily throat clearing, hoarseness, and voice strain are more common among those with diagnosed respiratory allergies, particularly among women.


Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Seasonal Allergy

Respiratory Allergies Linked to Frequent Vocal Symptoms, With Sofia Holmqvist-Jämsén, PhD

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

FDA approvals broaden ALYFTREK and TRIKAFTA eligibility to nearly 95% of US cystic fibrosis patients using a functional, mechanism-based variant criterion.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonary Fibrosis

FDA Expands CFTR Modulator Labels, Covering ~95% of US Cystic Fibrosis Patients

Learn smarter oral iron dosing: once daily or every other day to cut GI side effects, boost absorption, and avoid tea/coffee.

Latest News

ABCs in Dermatology: Late Breaking Data Spotlight at AAD 2026

Povorcitinib Delivers Deepening Responses Through 54 Weeks in Moderate-to-Severe HS, With Martina Porter, MD

Rethinking When and How to Treat IgA Nephropathy, With Sayna Norouzi, MD

Diabetes Dialogue: Orforglipron Receives FDA Approval for Chronic Weight Management

Mavacamten Safety and Real-World Data Emerging at ACC.26, With Matthew Martinez, MD